MedTech News
.................... by Andrew Celentano
FX Shoulder Solutions, Inc. Receives FDA 510(k) Clearance for FX V135® Easytech Shoulder System
ADDISON, Texas, May 5, 2026 /PRNewswire/ — FX Shoulder Solutions, Inc. has received FDA 510(k) clearance for the FX V135® Easytech Shoulder System, the next generation of stemless shoulder arthroplasty implants that provides surgeons with an anatomic stemless versus a modular stemmed-reverse option. This design enables surgeons to begin with a stemless approach and, when clinically appropriate, transition intraoperatively to a short stem solution without changing or adding another system.
Could Targeting Receptors From Inside the Cell Improve Metabolic Therapies?
Laidlaw Scholar Nikita Bhat has studied a new way to influence metabolic signaling with greater precision
Medtronic wins CE mark for VitalFlow ECMO transport tech
Medtronic (NYSE:MDT) announced today that it received CE mark approval for its VitalFlow Transport Frame Air and Ground (AG) accessory.
Ultrafast MRI uncovers brain signal direction: New scan may help decode autism, Alzheimer’s and hallucinations
Researchers at the Champalimaud Foundation in Lisbon have for the first time managed to identify with an imaging technique whether nervous impulses in the brain of rats are flowing in a “bottom-up” (feedforward), carrying information about visual input, or a “top-down” (feedback) direction, carrying information about expectations or predictions on a given task or about the perception of the world around us.
Low-dose eye drops can manage adult myopia for 24 hours
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia.
Omega-3 supplements may be linked to faster cognitive decline in seniors, study finds
A new study published in The Journal of Prevention of Alzheimer’s Disease suggests that these oral capsules may actually be linked to a faster decline in cognitive function.
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
Insulet starts study of closed loop insulin delivery system
Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.